Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Basket Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (Nmdar) Or Anti-Leucine-Rich Glioma-Inactivated 1 (Lgi1) Encephalitis
Sex at Birth: All
Condition: Autoimmune Encephalitis
Location: UH Cleveland Medical Center
The purpose of this study is to assess the effects, good or bad, of an investigational treatment in participants with autoimmune encephalitis. In the study, half of the participants will receive an investigational treatment, and the other half will receive a placebo. This investigational treatment is in addition to the continuation or completion of standard therapy for autoimmune encephalitis. The effects will be compared between those who receive investigational treatment and those who receive placebo. A placebo looks exactly like the study drug but has no active ingredient.
Who Can Participate
Participants 12 years old and older with onset of autoimmune encephalitis symptoms within the last 9 months may be eligible for this study.
- STUDYID: 2022-0853